Topical agents for the treatment of psoriasis, past, present and future

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

Dermatology and therapy·2026

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

Dermatology and therapy·2026

Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Pharmaceutical medicine·2026

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement.

JAMA dermatology·2026

Age- and Phenotype-Specific Patterns of Atopic and Autoimmune Comorbidities in Alopecia Areata: A Cross-Sectional Study.

Journal of cutaneous medicine and surgery·2026

Ocular Events Temporally Associated With Minoxidil: A Structured Review.

Journal of cutaneous medicine and surgery·2026

Geographic Distribution and Rural Access to General and Pediatric Dermatology in Canada: A Cross-Sectional Geospatial Analysis.

Journal of cutaneous medicine and surgery·2026

[Buprenorphine and pain management: Clinical insights and practical landmarks].

Therapie·2026

Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.

Handbook of experimental pharmacology·2026

Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?

The Journal of clinical endocrinology and metabolism·2026

Phosphate storm in chronic kidney disease-mineral and bone disorder: practical clinical strategies for vascular calcification control.

Nephron·2026

Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.

Immunity, inflammation and disease·2026

Intranasal midazolam vs mouth-dissolving clobazam in terminating seizures: A randomized controlled trial.

Epilepsia·2026

Related Experiment Videos

Topical agents for the treatment of psoriasis, past, present and future

Related Concept Videos

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study.

Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis.

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.

International Eczema Council Definitions of Low Disease Activity and Remission in Atopic Dermatitis: A Consensus Statement.

Age- and Phenotype-Specific Patterns of Atopic and Autoimmune Comorbidities in Alopecia Areata: A Cross-Sectional Study.

Ocular Events Temporally Associated With Minoxidil: A Structured Review.

Geographic Distribution and Rural Access to General and Pediatric Dermatology in Canada: A Cross-Sectional Geospatial Analysis.

[Buprenorphine and pain management: Clinical insights and practical landmarks].

Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.

Must RAAS-modifying drugs be withdrawn for the diagnosis of primary aldosteronism?

Phosphate storm in chronic kidney disease-mineral and bone disorder: practical clinical strategies for vascular calcification control.

Combination Treatment of IL-17 Inhibitor and JAK Inhibitor in Psoriatic Arthritis: A Case Report and Scoping Review.

Intranasal midazolam vs mouth-dissolving clobazam in terminating seizures: A randomized controlled trial.

Related Experiment Videos

Topical agents for the treatment of psoriasis, past, present and future

Related Concept Videos

Related Articles